Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia